Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothea Heersema

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of the Neurological Sciences|March 3, 2007
Progression in multiple sclerosis: further evidence of an age dependent processMarcus Koch, Jop Mostert, Dorothea Heersema, et al.
Journal of Neurology|February 24, 2007
Tremor in multiple sclerosisMarcus Koch, Jop Mostert, Dorothea Heersema, et al.
Journal of the Neurological Sciences|December 26, 2006
Plasma S100beta and NSE levels and progression in multiple sclerosisMarcus Koch, Jop Mostert, Dorothea Heersema, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Progression in familial and nonfamilial MSMarcus Koch, Maarten Uyttenboogaart, Marco Heerings, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2007
Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosisMarcus Koch, Jop Mostert, Alexander Arutjunyan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.
Journal of Neurology|May 6, 2014
Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center studyPeter Joseph Jongen, Dirk Lehnick, Jan Koeman, et al.
Trials|January 28, 2014
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trialMelissa Cambron, Jop Mostert, Patrick Haentjens, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of the Neurological Sciences|March 3, 2007
Progression in multiple sclerosis: further evidence of an age dependent processMarcus Koch, Jop Mostert, Dorothea Heersema, et al.
Journal of Neurology|February 24, 2007
Tremor in multiple sclerosisMarcus Koch, Jop Mostert, Dorothea Heersema, et al.
Journal of the Neurological Sciences|December 26, 2006
Plasma S100beta and NSE levels and progression in multiple sclerosisMarcus Koch, Jop Mostert, Dorothea Heersema, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Progression in familial and nonfamilial MSMarcus Koch, Maarten Uyttenboogaart, Marco Heerings, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2007
Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosisMarcus Koch, Jop Mostert, Alexander Arutjunyan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.
Journal of Neurology|May 6, 2014
Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center studyPeter Joseph Jongen, Dirk Lehnick, Jan Koeman, et al.
Trials|January 28, 2014
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trialMelissa Cambron, Jop Mostert, Patrick Haentjens, et al.
Pageof 1